
Mike Nally replaces Deepak Khanna as MSD head
pharmafile | December 11, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â ABPI, Deepak Khanna, MSD, mike nallyÂ
Merck Sharp & Dohme has confirmed that Mike Nally will succeed Deepak Khanna as managing director for MSD in the UK and Ireland from January.
Khanna who is also stepping down from another role next year at the ABPI, will now be appointed as a senior VP and regional president of its European Oncology unit from January.
Nally is currently managing director of MSD in Sweden and the firm says he has led the company to become a more customer-centric organisation.
Both positions will be based in the UK and Nally and Khanna will transition during January and February.
Khanna will remain in his role of president of the Association of the British Pharmaceutical Industry until the end of his term in April, when he is succeeded by Jonathan Emms.
Related Content

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

Merck shares data from phase 3 trial of Keytruda for gastric cancers
Merck, known as MSD outside of the US and Canada, has announced data from the …

Merck to acquire Harpoon Therapeutics for approximately $680m
Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced …






